Asthma
Conditions
Interventions
Standard therapy (the participants have used before participating the study) plus Clarithromycin 200 mg/day for 12 weeks, followed by Standard therapy alone for 12 weeks.
Standard therapy (the partici
Sponsors
Kyorin University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are diagnosed with asthma according to guidelines of The Japanese Respiratory Society and Japanese Society of Allergy. 2. Patients who meet our criteria of severe asthma with peripheral blood neutrophilia (white blood cell count >= 8,000 /microliter, neutrophil count >= 6,000 /microliter, or eosinophil count >= 72/microliter). 3. Patients who understand the purpose of the study and gave written informed consent. 4. Patients who are 20 years old or older.
Exclusion criteria
Exclusion criteria: 1. Patients with chronic obstructive lung disease. 2. Patient who smoked within three months. 3. Patients whose attending physician recommends not to participate the study because of comorbidities (i.e. respiratory infection, heart disease, liver disease, and kidney disease) 4. Patients with non-tuberculotic mycobacterial infection. 5. Patients who cannot use clarithromycin: with history of hypersensitivity to clarithromycin; using presently pimozide, Ergotamine Tartrate, Dihydroergotamine Mesilate, Tadalafil, Asunaprevir, Vaniprevir, or Suvorexant; with liver or kidney disease and using presently Colchicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exacerbation of asthma | — |
Countries
Japan
Contacts
Public ContactMasato Watanabe
Kyorin University Faculty of Medicine First Department of Internal Medicine (Respiratory Medicine)
Outcome results
None listed